Rubraca (rucaparib) — United Healthcare
Uterine leiomyosarcoma (uLMS)
Preferred products
- gemcitabine plus docetaxel
- doxorubicin
Initial criteria
- Diagnosis of BRCA altered uterine leiomyosarcoma (uLMS)
- Disease has progressed following prior treatment with one of the following: gemcitabine plus docetaxel OR doxorubicin
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Rubraca therapy
Approval duration
12 months